Search
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalIn fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.
Buserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalIt is used in prostate cancer treatment.
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB18750ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB22669ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB22671ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB31654ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Plasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with … [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia).
Suprofen
go.drugbank.com/drugs/DB00870ApprovedWithdrawnAn ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Cipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigational[L63931] Cipepofol is approved in the United States for induction of general anesthesia in adults undergoing surgery, an approval Haisco announced on June 1, 2026. … and maintenance of general anesthesia in children and adolescents.